Back

Effect of the ugt1a3*2 haplotype on pharmacokinetics and pharmacodynamics of atorvastatin in patients with coronary heart disease

23 April 2026 (08:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Heterogeneity of vascular and atherosclerotic risk phenotypes Pharmacogenetics Delegates Premium Access ESC Preventive Cardiology 2026 European Association of Preventive Cardiology (EAPC)

About the speaker

Photo
Ms Amara Synoeve Uduma

University of Oslo, Oslo (Norway)

4 More presentations in this session

Presentation thumbnail
Prognostic impact of total physiologic atherosclerotic burden and residual cholesterol risk in statin-treated patients undergoing PCI
Miss H. Sze (Hong Kong, HK)
Abstract Slides
Presentation thumbnail
Which stent wins? Nationwide insights on drug-eluting vs. non-drug-eluting stents in prostate cancer patients undergoing PCI
Doctor V. Sharma (Sayre, US)
Presentation thumbnail
Diagnostic role of aortic valve calcium scoring in aortic stenosis according to etiology
Doctor E. Shirka (Tirana, AL)
Presentation thumbnail
Efficacy of colchicine in reducing cardiovascular events in patients with low-to-normal LDL-C levels
Mrs T. Shengelia (Tbilisi, GE)
Abstract Slides

Access the full session

Session thumbnail
Heterogeneity of vascular and atherosclerotic risk phenotypes

The Event

Event poster

ESC Preventive Cardiology 2026

23 April - 25 April 2026
You may be interested in
thumbnail
Congress Presentation
Limited visibility and uptake of the clopidogrel pharmacogenomic guidelines among cardiologists
thumbnail
Congress Session
Pharmacogenetics: a tool to guide clinical decisions
thumbnail
Congress Presentation
CYP2C19 genetic variants and coronary atherosclerosis: insights beyond antiplatelet therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources